Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Closed 08-14 16:00:00 EDT

0.8340

+0.0340

+4.25%

盘后0.8050

-0.0290-3.48%

19:02 EDT

High0.8460	Low0.7832	Vol1.13M
Open0.8000	D1 Closing0.8000	Amplitude7.85%
Mkt Cap106.34M	Tradable Cap103.42M	Total Shares127.51M
T/O923.63K	T/O Rate0.91%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.834,"timestamp":1786737600000,"preClose":0.8,"halted":0,"volume":1126966,"hourTrading":{"tag":"盘后","latestPrice":0.805,"preClose":0.834,"latestTime":"19:02 EDT","volume":4063,"amount":3279.553,"timestamp":1786748546656,"change":-0.029,"changeRate":-0.034772,"amplitude":0.034772},"delay":0,"changeRate":0.0424999999999999,"floatShares":124000000,"shares":127510505,"eps":-0.323929,"marketStatus":"Closed","change":0.034,"latestTime":"08-14 16:00:00 EDT","open":0.8,"high":0.846,"low":0.7832,"amount":923633.15945,"amplitude":0.0785,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.323929,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.8,"preHourTrading":{"tag":"盘前","latestPrice":0.815,"preClose":0.8,"latestTime":"09:19 EDT","volume":706,"amount":561.7786024,"timestamp":1786713545832,"change":0.015,"changeRate":0.01875,"amplitude":0.03125},"postHourTrading":{"tag":"盘后","latestPrice":0.805,"preClose":0.834,"latestTime":"19:02 EDT","volume":4063,"amount":3279.553,"timestamp":1786748546656,"change":-0.029,"changeRate":-0.034772,"amplitude":0.034772},"volumeRatio":1.676444},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2659900262","title":"Oncolytics Net Loss Widens to $9.44 Million in Q2 2026; R&D Expenses More than Doubled to $4.26 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900262","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900262?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:22","pubTimestamp":1786566168,"startTime":"0","endTime":"0","summary":"Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 millionOncolytics Biotech posted a Q2 net loss of USD 9.44 million, widening from USD 5.28 million a yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLb4ZDkf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654037844","title":"Oncolytics Biotech Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2654037844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654037844?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:43","pubTimestamp":1784925833,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech gets Nasdaq notice for failing $1 minimum bid price ruleOncolytics Biotech received a Nasdaq notice for failing the $1 minimum bid price rule after ONCY closed below $1 for 30 strai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL3dh53V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652170216","title":"Oncolytics Biotech Announces Press Release Available","url":"https://stock-news.laohu8.com/highlight/detail?id=2652170216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652170216?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:23","pubTimestamp":1784553798,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech announces press release availableOncolytics Biotech disclosed FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.Designation t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL5gxmKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652216395","title":"Oncolytics Biotech Wins FDA Fast Track Status for Pelareorep in Second-line Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2652216395","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652216395?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:08","pubTimestamp":1784552882,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech wins FDA Fast Track status for pelareorep in second-line anal cancerOncolytics Biotech won FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or la","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL3bhsn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ONCY","IE00BGHQF748.EUR","BK4139","SG9999014021.USD","LU2095319765.USD","BK4112","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","NDAQ","BCDF","LU2210149790.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652215793","title":"Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-line and Later Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2652215793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652215793?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:00","pubTimestamp":1784552403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUAMQ1JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651143216","title":"Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651143216","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651143216?lang=en_us&edition=fundamental","pubTime":"2026-07-14 00:40","pubTimestamp":1783960807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stoke Therapeutics (STOK) and Oncolytics Biotech (ON...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-stoke-therapeutics-stok-and-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-stoke-therapeutics-stok-and-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4141","LU0724618433.USD","ON","BK4588","LU1861214812.USD","LU0029874061.USD","BK4512","LU2360107325.USD","LU0348723411.USD","LU1854104046.USD","LU1854103824.USD","LU1861220033.SGD","LU1978683503.SGD","BK4585","ONCY","STOK","LU2357305700.SGD","BK4605","LU1983260115.SGD","IE00BD6J9T35.USD","LABU","LU1861215975.USD","BK4581","LU0128526141.USD","IE00BZ199S13.USD","LU1720051017.SGD","BK4139","HCSG","XBI","LU1548497426.USD","LU0124384867.USD","XLV","LU1861219969.SGD","IE00BFMHRM44.USD","LU1720051108.HKD","LU2298322129.HKD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651112313","title":"Oncolytics Biotech to Meet FDA on Registrational Pathway for REO 033 Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651112313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651112313?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:30","pubTimestamp":1783949404,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech to meet FDA on registrational pathway for REO 033 colorectal cancer trialOncolytics Biotech will hold an FDA Type D meeting in the first half of August 2026 to discuss a registratio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL99jcG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651596114","title":"Oncolytics Biotech - Half of Reo 33 Clinical Sites to be Activated This Month; over 20 Patients Pre-identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2651596114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651596114?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC02CCX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145671","title":"Oncolytics Biotech - to Hold Type D FDA Meeting on Reo 33 Registration Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145671?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC02CCX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145181","title":"Oncolytics Biotech - Initial Reo 33 Part a Tumor Response Update Expected by Year-end 2026; Part B Enrollment May Begin Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145181?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC02CCX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651114562","title":"Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized Ras-mutant Mss Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651114562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651114562?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC02CCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651114552","title":"Oncolytics Biotech - Remaining Reo 33 Sites to be Activated by End of August for Accelerated Enrollment in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651114552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651114552?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC02CCX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915034","title":"Oncolytics Biotech Swaps Auditor Ernst & Young for Baker Tilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915034","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915034?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:24","pubTimestamp":1783542244,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech swaps auditor Ernst & Young for Baker TillyOncolytics Biotech switched auditors, disengaging Ernst & Young on July 6, 2026, citing a corporate restructuring.Baker Tilly US was engag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLbf14cM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644761439","title":"Sector Update: Healthcare Stocks Advance in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2644761439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644761439?lang=en_us&edition=fundamental","pubTime":"2026-06-17 01:29","pubTimestamp":1781630950,"startTime":"0","endTime":"0","summary":"Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF  each adding 0.2%.The iShares Biotechnology ETF  was down 0.2%.In corporate news, GSK  said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk  plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly  submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech  shares jumped past 10% after it said Tuesday it has received a US pate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LLY","IE00BJLML261.HKD","LU0787776722.HKD","LU0109391861.USD","LU1917777945.USD","LU1280957306.USD","LU0823434740.USD","IE00B4R5TH58.HKD","LU2750360997.AUD","IE00BKDWB100.SGD","BK4588","LU0964807845.USD","LU2360106947.USD","LU1868836914.USD","IE00B4JS1V06.HKD","LU2462157665.USD","LU1232071149.USD","LU0096364046.USD","LU2471134523.USD","SG9999015978.USD","BK4581","BK4007","BK4585","LU0353189763.USD","LU0061475181.USD","LU0882574055.USD","LU0456855351.SGD","LU1093756325.SGD","LU0320765059.SGD","NVOH","LU1720051108.HKD","SG9999013999.USD","LU1804176565.USD","IE0004445239.USD","LU2324357040.USD","IE00BWXC8680.SGD","LU1023059063.AUD","LU2237443978.SGD","LU2471134796.USD","LU1868836591.USD","ELIS","LU0882574139.USD","LU2023251221.USD","BK4516","IE00BJJMRY28.SGD","IE00BN29S564.USD","LU0316494557.USD","LU2213496289.HKD","LU2237443549.SGD","IE00BK4W5L77.USD","LU1712237335.SGD","LU0820561818.USD","LU1629891620.HKD","IE00BFSS8Q28.SGD","LU1868837300.USD","SGXZ57979304.SGD","LU2106854487.HKD","LU0466842654.USD","LU2456880835.USD","LU2108987350.USD","GSK.UK","NVO","LU2168564149.EUR","IE00BKVL7J92.USD","LU0432979614.USD","LU1064131342.USD","LU2236285917.USD","LU2237443895.HKD","BK4533","SG9999014898.SGD","SG9999015952.SGD","SGXZ81514606.USD","LU2361044949.HKD","LU0889565916.HKD","LU0203202063.USD","LU1366192091.USD","IE00BZ1G4Q59.USD","LU0820561909.HKD","LU0109394709.USD","SG9999014914.USD","LU0158827948.USD","LU0256863811.USD","LU2491050154.USD","SGXZ51526630.SGD","SGXZ99366536.SGD","LU0708995401.HKD","LU2361045086.USD","SG9999015945.SGD","LU2211815571.USD","SG9999014906.USD","LU0203201768.USD","NVOX","LU0672654240.SGD","SGXZ31699556.SGD","LU0114720955.EUR","LU0820562030.AUD","LLYZ","LU1057294990.SGD","LU1551013342.USD","LU0289739699.SGD","LU1291159041.SGD","IE0001KFT4U8.USD","IE00BJJMRZ35.SGD","LU0471298777.SGD","IE00BK4W5M84.HKD","LU1093756168.USD","ELIL","LU2028103732.USD","LU0943347566.SGD","LU0417517546.SGD","IE00BKPKM429.USD","LU0094547139.USD","IE00B1XK9C88.USD","LU0133085943.USD","LU0354030511.USD","LU1267930730.SGD","LU1035775433.USD","LU2089984988.USD","LU0266013472.USD","LLYX","LU2237438978.USD","LU0323591593.USD","LU1974910355.USD","LU2471134952.CNY","LU1868837136.USD","IE00B775H168.HKD","LU1983299246.USD","LU2023250330.USD","LU2746668974.SGD","SG9999018865.SGD","LU0238689110.USD","LU0683600562.USD","LU1069344957.HKD","LU0353189680.USD","LU2111349929.HKD","LU2168563687.JPY","LU2087625088.SGD","LU2168564222.USD","LU2602419157.SGD","IE00B7KXQ091.USD","IE0009355771.USD","LU2357305700.SGD","SG9999017495.SGD","LU0158827781.USD","GSK","LU0079474960.USD","LU0225283273.USD","LU1127390331.HKD","SG9999014880.SGD","IE0005OL40V9.USD","LU1829250122.USD","LU2491049909.HKD","LU2089284900.SGD","LU0640476718.USD","LU1988902786.USD","LU2168564065.EUR","LU0823416689.USD","LU2746668461.USD","IE00B1BXHZ80.USD","LU2756315318.SGD","LU0234572021.USD","IE00BFSS7M15.SGD","SG9999001176.USD","LU1989771016.USD","SG9999015986.USD","LU2237443382.USD","LU2896262040.SGD","LU2264538146.SGD","IE0004445015.USD","BK4599","LU0471298694.HKD","LU0823434583.USD","LU2461242641.AUD","LU0385154629.USD","LU2750360641.GBP","LU0097036916.USD","IE0002141913.USD","SG9999001176.SGD","LU2471134879.HKD","IE00B2B36J28.USD","LU0006306889.USD","LU0058720904.USD","LU0320765992.SGD","LU2552382132.HKD","LU2491050071.SGD","LU2237443622.USD","LU0198837287.USD","IE00BFTCPJ56.SGD","LU2756315664.SGD","LLII","LU1623119135.USD","LU2265009873.SGD","LU2552382215.SGD","ONCY","LU1551013425.SGD","LU0256863902.USD","BK4139","LU2168564495.EUR","LU0210536198.USD","LU0689472784.USD","LU1548497426.USD","LU2361044865.SGD","IE00BJT1NW94.SGD","LU0106261372.USD","LU2063271972.USD","LU2112291526.USD","LU2468319806.SGD","LU0354030438.USD","BK4532","LU1061106388.HKD","LU0786609619.USD","LU2552382058.USD","LU1720051017.SGD","LU2417539215.USD","SG9999018857.SGD","IE00BJJMRX11.SGD","LU1868836757.USD","GB00BDT5M118.USD","LU2089283258.USD","LU1814569148.SGD","GSKH","LU1145028129.USD","LU2271345857.HKD","LU2023250504.SGD","LU1323610961.USD","BK4534","LU0122379950.USD","LU0154236417.USD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643633947","title":"Oncolytics Gets US Patent for Pelareorep Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2643633947","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643633947?lang=en_us&edition=fundamental","pubTime":"2026-06-16 22:17","pubTimestamp":1781619432,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech (ONCY) said Tuesday it has received a US patent covering pelareorep manufacturing process into 2044.The firm also said it plans to file additional patent applications this year to e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643683187","title":"Oncolytics secures new patent for pelareorep manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643683187","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643683187?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:38","pubTimestamp":1781617100,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced that the United States Patent and Trademark Office has issued a new patent protecting its proprietary manufactu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-secures-new-patent-for-pelareorep-manufacturing-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-secures-new-patent-for-pelareorep-manufacturing-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","ONCY","XBI","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643577467","title":"Oncolytics Biotech wins new US manufacturing patent for pelareorep, protection through 2044","url":"https://stock-news.laohu8.com/highlight/detail?id=2643577467","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643577467?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:01","pubTimestamp":1781614901,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech secured a new U.S. patent covering its commercial-scale manufacturing process for pelareorep, with protection expected to run into 2044.A separate method-of-use patent application for pelareorep as an immunotherapy remains under review, with potential protection into 2046 if issued.Additional patent applications are planned in 2026 to expand protection for pelareorep across more uses and combination approaches.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL6JWzMh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","ONCY","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757222","title":"Oncolytics Biotech - Announces New U.S. Patent for Pelareorep Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757222?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:00","pubTimestamp":1781614852,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640817181","title":"Oncolytics Biotech COO John Bearden McAdory files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640817181","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640817181?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:32","pubTimestamp":1780518754,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech COO McAdory John Bearden reported holding stock options for 500,000 common shares exercisable at $0.97, expiring Jan. 12, 2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL9SyNHR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640769181","title":"Oncolytics Biotech director Stephen C. Glover files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640769181","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640769181?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:31","pubTimestamp":1780518718,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech director Stephen C. Glover filed an initial Form 3 statement of beneficial ownership dated June 1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL5ph5H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":-0.1191},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.2453},{"period":"1year","weight":-0.2157},{"period":"ytd","weight":-0.0847}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.375,"avgChangeRate":0.014597},{"month":6,"riseRate":0.25,"avgChangeRate":0.155922},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014421},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.07525},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction